Авторы

  • Parpibaeva D.A., Buvamukhamedova N.T.

Ключевые слова:

non-alcoholic fatty liver disease (NAFLD); metabolically associated fatty liver disease (MAFLD); non-alcoholic steatohepatitis (NASH); metabolically associated steatohepatitis (MASH); liver; biomarkers

Библиографические ссылки

Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209.

Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986.

Singh A, Sohal A, Batta A. Recent developments in non-invasive methods for assessing metabolic dysfunction-associated fatty liver disease. World J Gastroenterol. 2024;30(39):4324–4338.

Hudson D, Afzaal T, Bualbanat H, et al. Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the shift from biopsy to non-invasive techniques. Ther Adv Gastroenterol. 2024;17:1–14.

Abdelhameed F, Kite C, Lagojda L, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of MASLD. Curr Obes Rep. 2024;13:510–531.

Das S, Agarwal K, Kapoor N, et al. Emerging concepts in the diagnosis and management of MAFLD. Curr Opin Endocrinol Diabetes Obes. 2025; 32(6):269–278.

Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with metabolic fatty liver disease. Gastroenterology. 2019;156(5):1264–1281.

Younossi ZM, Golabi P, de Avila L, et al. Global epidemiology of metabolic associated fatty liver disease. Hepatology. 2023;77(4):1335–1347.

Wong VW, Adams LA, de Lédinghen V, et al. Noninvasive biomarkers in NAFLD and MAFLD. Nat Rev Gastroenterol Hepatol. 2018;15(8):461–478.

Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography. Clin Gastroenterol Hepatol. 2018;16(5): 640–649.

Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter for diagnosing steatosis. J Hepatol. 2017;66(5):1022–1030.

Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis. Clin Gastroenterol Hepatol. 2017;15(10):1619–1627.

Al-Huneidi LI, Zhao F, Maas R, et al. Liver fat quantification by MRI-PDFF: systematic review and meta-analysis. J Gastroenterol Hepatol. 2025;40 (12):2808–2819.

Shao C, Ye J, Li X, et al. Discrepancies between NAFLD and MAFLD by steatosis assessment tools. J Clin Transl Hepatol. 2022;10(6):1013–1026.

Chinese Society of Hepatology. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (2024). Hepatobiliary Surg Nutr. 2024;13(5):827–846.

Алимухамедов Д. Ш. Режим питания при атеросклерозе и других заболеваниях системы кровообращения //Болезни кровообращения. – 2025. – Т. 1. – №. 4. – С. 30-34.

Бурибоев Э. М., Азизова Ф. Л. Метабиологическое действие табачных изделий на иммунитет человека //Oriental renaissance: Innovative, educational, natural and social sciences. – 2022. – Т. 2. – №. 12. – С. 213-218.